Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SSP-004184AQ · 1 trial · 1 indication
AUC 0-last is the area under the plasma concentration versus time curve from time 0 to the time of last quantifiable concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body
AUCinf is the area under the curve extrapolated to infinity, calculated using the observed value of the last nonzero concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated
| Arm | Type | Description |
|---|---|---|
| SSP-004184AQ (single dose) | EXPERIMENTAL | 40 mg/kg (oral capsule form) given once on Day 1 |
| SSP-004184SS (single dose) | EXPERIMENTAL | 21.8 mg/kg (oral capsule form) given once on Day 1 |
| SSP-004184AQ (2 doses) | EXPERIMENTAL | 40 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1 |
| SSP-004184SS (2 doses) | EXPERIMENTAL | 21.8 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1 |
| Name | Type | Description |
|---|---|---|
| SSP-004184AQ | DRUG | Magnesium salt |
| SSP-004184SS | DRUG | Disodium salt |
Inclusion Criteria: * Age 18-65 years * Must be considered "healthy". * Serum ferritin \>20ng/mL, hemoglobin \>125g/L and erythrocyte indices within normal range Exclusion Criteria: * Subject has a clinically significant history or a disorder detected during the medical interview/physical examina...
SSP-004184AQ is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial assessing its relative bioavailability. The drug is not approved and remains under investigation by its developer.
SSP-004184AQ is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is conducting clinical research on this investigational small molecule, which is currently in Phase 1 development.
SSP-004184AQ is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not been approved for any use and is still undergoing clinical evaluation.
SSP-004184AQ has one completed Phase 1 trial, NCT01905540, titled "A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-004184SS (Disodium Salt)." The study enrolled 28 healthy volunteers in the United States and was controlled but not double-blinded.
SSP-004184AQ and SSP-004184SS are related but distinct forms of the same investigational drug. The completed Phase 1 trial compared the relative bioavailability of SSP-004184AQ, a magnesium salt, and SSP-004184SS, a disodium salt, in healthy volunteers.